KN-044 |
KN-044 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours |
Details
|
IO-102 |
IO-102 |
Phase 2 Clinical |
Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech |
Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
ATOR-1015 |
ADC-1015; ATOR-1015 |
Phase 1 Clinical |
Alligator Bioscience |
Solid tumours |
Details
|
Anti-CTLA-4 monoclonal antibody (Regeneron) |
REGN-4659 |
Phase 1 Clinical |
Regeneron Pharmaceuticals Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
BA3017 |
BA-3017; BA3017 |
Phase 1 Clinical |
Bioatla |
Neoplasms |
Details
|
BT-001 |
BT-001 |
Phase 2 Clinical |
Transgene |
Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma |
Details
|
ONC-392 |
ONC-392 |
Phase 1 Clinical |
Oncoimmune |
Small Cell Lung Carcinoma; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Solid tumours; Pancreatic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
BMS-986249 |
BMS-986249 |
Phase 2 Clinical |
Cytomx Therapeutics |
Neoplasms |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) |
|
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma |
Details
|
ADG-126 |
|
Phase 1 Clinical |
Adagene Inc |
Neoplasms |
Details
|
XTX-101 |
XTX-101 |
Phase 2 Clinical |
|
Solid tumours |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|
RP-2 |
RP-2 |
Phase 1 Clinical |
Replimune, Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) |
|
Phase 2 Clinical |
Hualan Genetic Engineering Co Ltd |
Melanoma |
Details
|
TWP-102 |
TWP-102 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
JS-007 |
JS-007 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Neoplasms; Lung Neoplasms; Melanoma |
Details
|
Recombinant human anti-CTLA-4 monoclonal antibody (Mab-Venture/ShuangLu Pharmaceutical) |
|
Phase 1 Clinical |
Mab-Venture Biopharm Co Ltd, Beijing Sl Pharmaceutical Co Ltd |
Solid tumours |
Details
|
CS-1002 |
CS-1002 |
Phase 1 Clinical |
Cstone Pharmaceuticals |
Solid tumours |
Details
|
BAT-4706 |
BAT-4706 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Melanoma |
Details
|
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
GI-101 |
GI-101 |
Phase 2 Clinical |
|
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
Vudalimab |
XmAb-20717; XmAb-717 |
Phase 2 Clinical |
Xencor |
Nasopharyngeal Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Endometrial Neoplasms; Colorectal Neoplasms; Astrocytoma; Vulvar Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Adnexal Diseases; Mesothelioma; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours |
Details
|
SI-B003 |
SI-B003 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
BCD-217 |
BCD-217 |
Phase 2 Clinical |
Biocad |
Melanoma |
Details
|
SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota |
Glioblastoma |
Details
|
Erfonrilimab |
KN-046; KN046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics |
Solid tumours |
Details
|
ALPN-202 |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences |
Solid tumours; Lymphoma |
Details
|
RP-3 |
RP-3 |
Phase 1 Clinical |
Replimune Inc |
Solid tumours |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase 1 Clinical |
Medimmune Llc |
Solid tumours; Carcinoma, Renal Cell; Neoplasms |
Details
|
Zalifrelimab |
AGEN-1884; RebmAb-600 |
Phase 2 Clinical |
4-Antibody, Ludwig Institute For Cancer Research |
Solid tumours; Hemangiosarcoma; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine |
IO-102/IO-103 |
Phase 3 Clinical |
Herlev Hospital |
Melanoma |
Details
|
QL-1706 |
QL-1706; PSB-205 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms |
Details
|
ADG-116 |
ADG-116 |
Phase 2 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours; Neoplasms |
Details
|
Botensilimab |
AGEN-1181 |
Phase 2 Clinical |
Agenus Inc |
Neoplasms |
Details
|
Lorigerlimab |
MGD-019 |
Phase 1 Clinical |
Macrogenics |
Skin Melanoma; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bavunalimab |
XmAb-22841; XmAb-841 |
Phase 1 Clinical |
Xencor |
Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell |
Details
|
RIVAL-01 |
TBio-6517; TAK-605 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd, Turnstone Biologics |
Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms |
Details
|
IMM-27M |
IMM27M; IMM-27M |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
BA-3071 |
BA-3071; CAB-CTLA-4 |
Phase 2 Clinical |
Beigene Ltd, Bioatla |
Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular |
Details
|
HBM-4003 |
HBM-4003 |
Phase 2 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
YH-001 |
YH-001 |
Phase 2 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Quavonlimab |
AK-107; MK-1308 |
Phase 2 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Ipilimumab biosimilar (Innovent Biologics) |
IBI-310 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Liver Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
Tremelimumab |
CP-675; CP-675206 |
Phase 3 Clinical |
Pfizer Inc |
Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Urogenital Neoplasms; Carcinoma, Pancreatic Ductal; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Digestive System Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; HIV Infections; Head and Neck Neoplasms; Liver Neoplasms; Solid tumours |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|